Cagrilintide is a long-acting analogue of amylin, a naturally occurring peptide that is released in conjunction with insulin. Cagrilintide has shown promise in animal trials as a treatment for obesity and type 2 diabetes. It has been studied for benefits not just in type 2 diabetes, but for liver damage, alcohol-related liver disease, and heart/blood vessel disease. There is some speculation about the role of this peptide in Alzheimer’s disease as well, but no research has been published in that particular sub-domain, yet. Many trials, however, have looked at the combination of cagrilintide and semaglutide in the treatment of obesity and type 2 diabetes. The two proteins appear to work synergistically to provide more robust and more permanent weight loss effects. It is important to note that while preclinical studies suggest promising therapeutic potential, clinical trials in humans are limited. Further research needs to be done to determine the efficacy and safety profiles.

Methylene Blue is a well-studied redox-active compound, meaning it can both donate and accept electrons — a key function in cellular energy processes. This allows it to enhance mitochondrial function by supporting the electron transport chain, improving ATP production and reducing oxidative stress. Research shows it also modulates inflammatory pathways and protects mitochondrial integrity. Methylene Blue is studied for its neuroprotective, metabolic, and anti-aging properties, making it a promising compound for brain health and cellular resilience.